scholarly journals Laparoscopic gastric wedge resection as the method of choice in the treatment of gastrointestinal stromal tumors: A case report

2016 ◽  
Vol 144 (3-4) ◽  
pp. 211-214
Author(s):  
Dejan Stevanovic ◽  
Dragos Stojanovic ◽  
Damir Jasarovic ◽  
Nebojsa Mitrovic ◽  
Zorana Bokun-Vukasinovic
Keyword(s):  
Gastrointestinal Tract ◽  
Gastrointestinal Stromal Tumors ◽  
Histological Grade ◽  
Wedge Resection ◽  
Gastric Gist ◽  
Histopathological Analysis ◽  
Primary Therapy ◽  
Mesenchymal Tumors ◽  
Stromal Tumors ◽  
Common Group

Introduction. The gastrointestinal stromal tumors (GIST) are the most frequent mesenchymal tumors of the gastrointestinal tract. The surgery of resectable gastric GIST is the primary therapy for these tumors, but the decision regarding the surgical radicality of the procedures is still a point of discussion among surgeons and oncologists. Case Outline. A 74-year-old patient was admitted to hospital with signs of bleeding from the upper parts of the gastrointestinal tract. Urgent gastroscopy was performed and a subepithelial gastric lesion with bleeding ulceration was noted in the region of the fornix. A computed tomography scan of the abdomen showed a tumor in the fornix region with the dimensions of 48 ? 32 mm, which was growing mostly intraluminally. After an adequate preoperative preparation the patient underwent a laparoscopic wedge resection of gastric fornix with intramural tumor lesion. The histopathological analysis of the specimen showed a well differentiated GIST (histological grade G1), of the spindle cell type. Based on the immunohistochemical analysis of the specimen it was concluded that the patient was in the IA stage of the disease with a low risk of malignant progression. In the population of patients with GIST, this is the most common group (43%), with low malignant potential, and relapses present in only 3.6% of cases. The patient started with oral food intake on the first postoperative day, the first bowel movement occurred 36 hours after surgery, and the patient was released from hospital on the fourth postoperative day. Conclusion. Based on the aforementioned, we consider that the laparoscopic gastric wedge resection is a safe and efficient surgical procedure. This is primary therapy for most common group of patients with resectable gastric GIST.

Large Omental Metastases of a Gastrointestinal Stromal Tumor

Medicina ◽  
2011 ◽  
Vol 47 (11) ◽  
pp. 86
Author(s):  
Povilas Ignatavičius ◽  
Tomas Petraitis ◽  
Žilvinas Saladžinskas ◽  
Lilija Butkevičienė ◽  
Kristina Žvinienė
Keyword(s):  
Case Report ◽  
Gastrointestinal Tract ◽  
Gastrointestinal Stromal Tumor ◽  
Gastrointestinal Stromal Tumors ◽  
Interstitial Cells Of Cajal ◽  
Metastatic Tumor ◽  
Stromal Tumor ◽  
Mesenchymal Tumors ◽  
Stromal Tumors ◽  
Cells Of Cajal

Gastrointestinal stromal tumors are rare tumors, originating from the interstitial cells of Cajal. They are the most common mesenchymal tumors of the gastrointestinal tract. Metastatic tumor is treated with imatinib mesylate. A case of large metastases of a gastrointestinal stromal tumor to the omentum, diagnosis and treatment principles are presented in this case report.

scholarly journals Study of gastrointestinal stromal tumors with c-kit immunostaining

1970 ◽  
Vol 1 (1) ◽  
pp. 41-44
Author(s):  
B Sigdel ◽  
S Vaidya ◽  
Sabira KC
Keyword(s):  
Small Intestine ◽  
Gastrointestinal Tract ◽  
High Power ◽  
Gastrointestinal Stromal Tumors ◽  
Cystic Degeneration ◽  
Age Group ◽  
Mesenchymal Tumors ◽  
Stromal Tumors ◽  
Study Results ◽  
Microscopic Features

Background: Mutation of the C-KIT oncogene is the central event in gastrointestinal stromal tumors which are the most common mesenchymal tumors arising from the tubular gastrointestinal tract. Materials and Methods: A study was conducted in Patan hospital from April 2003 to May 2010. Mesenchymal tumors arising from the tubular gastrointestinal tract with the microscopic features suggesting gastrointestinal stromal tumor were included in the study. Results: A total of 22 cases were studied. The incidence was highest amongst the older age group (86.36%), than in younger people (13.63%). The tumor most commonly involved the small intestine (54.54%), followed by the stomach (36.36%). Most (59.09%) of the tumors were of huge size measuring >100 mm, and showed necrosis, hemorrhage and cystic degeneration. Mitotic activity was high (>5/50 high power fields) in 55% of the cases. Conclusion: C-KIT immunostaining showed positivity in 19 (86.36%) of the tumors in this study. Mutation of the C-KIT oncogene is seen in most of the gastrointestinal stromal tumors. Keywords: Gastrointestinal; Stromal tumors; C-KIT oncogene DOI: 10.3126/jpn.v1i1.4450 Journal of Pathology of Nepal (2011) Vol.1, 41-44

scholarly journals Gastrointestinal Stromal Tumors of the Distal Gastrointestinal Tract

2018 ◽  
Vol 31 (05) ◽  
pp. 295-300 ◽  
Author(s):  
Katherine Kelley ◽  
Raphael Byrne ◽  
Kim Lu
Keyword(s):  
Gastrointestinal Tract ◽  
Medical Therapy ◽  
Gastrointestinal Stromal Tumors ◽  
Molecular Classification ◽  
Review Article ◽  
Molecular Characteristics ◽  
Mesenchymal Tumors ◽  
Stromal Tumors ◽  
Improved Outcomes

AbstractGastrointestinal stromal tumors (GISTs) are rare in occurrence, but comprise the most common mesenchymal tumors of the gastrointestinal tract and affect between 15 and 20 individuals per million per year. Due to recent advancements in molecular classification of these tumors, medical therapy has provided improved outcomes to a historically surgically managed disease. This review article briefly discusses the molecular characteristics, medical and surgical therapies, and future of GIST management.

scholarly journals Extra - Intestinal Gastrointestinal Stromal Tumor of Omentum

2014 ◽  
Vol 4 (8) ◽  
pp. 682-684
Author(s):  
S Basnet ◽  
A Lakhey
Keyword(s):  
Gastrointestinal Tract ◽  
Gastrointestinal Stromal Tumor ◽  
Gastrointestinal Stromal Tumors ◽  
Rare Case ◽  
Stromal Tumor ◽  
Malignant Neoplasms ◽  
Mesenchymal Tumors ◽  
Stromal Tumors ◽  
Rare Tumors

Gastrointestinal stromal tumors are rare tumors, constituting less than 3% of all gastrointestinal malignant neoplasms but are the most common mesenchymal tumors of the gastrointestinal tract. Approximately 10% of gastrointestinal stromal tumors are extraintestinal and mostly arise from the mesentery or omentum. Here we report a rare case of an extraintestinal gastrointestinal stromal tumor of mesentery. Morphological and immunohistochemical features led to a diagnosis of extra-gastrointestinal stromal tumor.DOI: http://dx.doi.org/10.3126/jpn.v4i8.11610 Journal of Pathology of Nepal; Vol.4,No. 8 (2014) 682-684

scholarly journals Gastrointestinal stromal tumors (GIST) of the stomach as a cause of upper gastrointestinal bleeding

2007 ◽  
Vol 54 (1) ◽  
pp. 115-118 ◽  
Author(s):  
K. Ebrahimi ◽  
D. Velickovic ◽  
B. Spica ◽  
P. Sabljak ◽  
M. Bjelovic ◽  
...  
Keyword(s):  
Smooth Muscle ◽  
Gastrointestinal Tract ◽  
Gastrointestinal Stromal Tumors ◽  
Kinase Inhibitor ◽  
Mass Effect ◽  
Mesenchymal Tumor ◽  
Intestinal Cell ◽  
Gastric Gist ◽  
Stromal Tumors ◽  
Significant Difference

Gastrointestinal stromal tumors (GIST) is the most common mesenchymal tumor of the gastrointestinal tract. GIST is currently defined as a gastrointestinal tract mesenchymal tumor containing spindle cells (less commonly epitheloid cells or rarely both) and showing CD 117 (c-kit protein) positivity in more than 95% of cases. Although they may arise throughout the gut, the commonest site are stomach (60-70%), small intestine (20-30%), colorectum (5%) and esophagus (up to 5%). Rarely, GISTs develop in the retroperitoneum, omentum or mesentery. GIST originates from the intestinal cell of Cajal (ICC). ICCs are located in and around the myenteric plexus and are thought to function as intestinal pacemaker cells. Historically, GIST were often misclassified as leiomyomas or leiomyosarcomas. Subsequently, it has been determined that GISTs have distinct ultrastructural features and immunophenotypical markers compared with smooth muscle and smooth muscle tumors. GIST predominantly occur in middle aged and older patients, with no significant difference in the sex incidence. Data from the recent population study suggest an incidence of about 10-22 cases per million persons per year. Clinical presentation of GIST varies widely, and depends on tumor size and location. GISTs that caused symptoms tended to be larger with an average size of 6cm versus 2cm for asymptomatic GISTs. Symptoms are most commonly related to mass effect or bleeding. GISTs can grow very large before producing symptoms. Commonest symptom of gastric GIST is manifest or occult bleeding. Abundant, life-threatening bleeding that require urgent surgery is rare. For patient with primary, localized, nonmetastatic GIST, complete surgical resection represents the only chance for cure. Lymhadenectomy is not necessary, because lymph node metastasis is very rare. The 5 year survival rate in patients with resected primary GISTs ranges from 48-65%. Conventional che- Br. 1 GIST zeluca kao uzrok krvarenja iz gornjih partija 117 digestivnog trakta motherapy and radiation therapy is ineffective in the treatment of GIST. Imatinib mesilate (a tyrosine kinase inhibitor) was confirmed to be effective against metastatic or unresectable GISTs.

Resection of esophageal gastrointestinal stromal tumors.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. e20503-e20503
Author(s):  
Vladimir Trifanov ◽  
Oleg I Kit ◽  
Liubov Yu Vladimirova ◽  
Dmitriy Trifanov ◽  
Vadim Kasatkin
Keyword(s):  
Gastrointestinal Tract ◽  
Gastrointestinal Stromal Tumors ◽  
Kinase Inhibitors ◽  
Mitotic Rate ◽  
Endoscopic Biopsy ◽  
Surrounding Tissue ◽  
Mesenchymal Tumors ◽  
Management Guidelines ◽  
Stromal Tumors ◽  
Right Lobe

e20503 Background: Gastrointestinal stromal tumors (GIST) are the most common mesenchymal tumors of gastrointestinal tract. GISTs account for 0,1% to 0,3% of all tumors in the gastrointestinal tract. Two thirds of these tumors arise from the stomach, 25% arise from the small intestine and less than 5% arise from esophagus. Use of tyrosine kinase inhibitors has revolutionized therapy for GISTs but complete resection remains the treatment of choice. Methods: We report our experience (from 2005 to 2011) with five patients who underwent resection of esophageal GIST. Reviewed consensus management guidelines and performed a literature review for reported cases. Results: All five patients underwent surgery intervention at our institute. Four patients had no metastasis and they underwent tumor enucleation. Due to submucosal location only one of them was diagnosed with GIST by endoscopic biopsy before surgery. One patient had a giant liver metastasis invading totally all segments of right lobe of liver. He underwent transhiatal extirpation simultaneously combined with extended right-sided hemihepatectomy. That patient suffered from total dysphagia, 15 kg weight loss, gastrointestinal bleeding and a big lump in his right hypochondrium. After laparotomy we diagnosed big metastatic nodule invading the whole right lobe of liver 25 cm in diameter. After diaphragmotomy we diagnosed tumor of the lower third of esophagus. Consequently, we performed extended right-sided hemihepatectomy and transhiatal esophagus extirpation. Two months later esophageal plastics by means of ileocaecal segment of colon was performed. The pathological diagnosis was confirmed in all five cases by microscopic examination (KIT+; CD17+, mitotic rate). In adjuvant regime imatinib (400 mg/body/day) was administered for a year for all five patients. The patients are alive now, they were followed up every six months with CT for two years. Fortunately, no new tumors were observed during this period of time. Conclusions: Esophagectomy is the treatment of choice for esophageal GISTs but requires attention to operative details that emphasize complete en block excision of surrounding tissue and metastatic nodules.

Multislice imaging of gastrointestinal stromal tumors

2018 ◽  
pp. 3-14
Keyword(s):  
Computed Tomography ◽  
Key Words ◽  
Gold Standard ◽  
Gastrointestinal Stromal Tumors ◽  
Mesenchymal Tumors ◽  
Stromal Tumors ◽  
Preferential Localization ◽  
Multislice Imaging ◽  
Computed Tomography Diagnosis

Gastrointestinal stromal tumors (GIST) are the most common mesenchymal tumors of the digestive tract (1%). These tumors express the CD 117 in 95% of cases. The stomach is the preferential localization (70%). Diagnosis is difficult and sometimes late. Progress of imaging has greatly improved the management and the prognosis. Computed tomography (CT) is the gold standard for diagnosis, staging, and treatment follow-up. The increasing recognition of GIST’s histopathology and the prolonged survival revealed some suggestive imaging aspects. Key words: gastro-intestinal stromal tumors; computed tomography; diagnosis

scholarly journals Gastrointestinal Stromal Tumors (GISTs): Novel Therapeutic Strategies with Immunotherapy and Small Molecules

2021 ◽  
Vol 22 (2) ◽  
pp. 493
Author(s):  
Christos Vallilas ◽  
Panagiotis Sarantis ◽  
Anastasios Kyriazoglou ◽  
Evangelos Koustas ◽  
Stamatios Theocharis ◽  
...  
Keyword(s):  
Tyrosine Kinase ◽  
Tyrosine Kinase Inhibitors ◽  
Gastrointestinal Stromal Tumors ◽  
Kinase Inhibitors ◽  
Checkpoint Inhibitors ◽  
Survival Rates ◽  
Cancer Therapeutics ◽  
Gastrointestinal Neoplasms ◽  
Mesenchymal Tumors ◽  
Stromal Tumors

Gastrointestinal stromal tumors (GISTs) are the most common types of malignant mesenchymal tumors in the gastrointestinal tract, with an estimated incidence of 1.5/100.000 per year and 1–2% of gastrointestinal neoplasms. About 75–80% of patients have mutations in the KIT gene in exons 9, 11, 13, 14, 17, and 5–10% of patients have mutations in the platelet-derived growth factor receptor a (PDGFRA) gene in exons 12, 14, 18. Moreover, 10–15% of patients have no mutations and are classified as wild type GIST. The treatment for metastatic or unresectable GISTs includes imatinib, sunitinib, and regorafenib. So far, GIST therapies have raised great expectations and offered patients a better quality of life, but increased pharmacological resistance to tyrosine kinase inhibitors is often observed. New treatment options have emerged, with ripretinib, avapritinib, and cabozantinib getting approvals for these tumors. Nowadays, immune checkpoint inhibitors form a new landscape in cancer therapeutics and have already shown remarkable responses in various tumors. Studies in melanoma, non-small-cell lung cancer, and renal cell carcinoma are very encouraging as these inhibitors have increased survival rates. The purpose of this review is to present alternative approaches for the treatment of the GIST patients, such as combinations of immunotherapy and novel inhibitors with traditional therapies (tyrosine kinase inhibitors).

scholarly journals Skeletal Muscle Metastasis of a GIST: A Case Report and Review of the Literature

2016 ◽  
Vol 2016 ◽  
pp. 1-5
Author(s):  
Olga D. Savvidou ◽  
George D. Chloros ◽  
Georgios D. Agrogiannis ◽  
Penelope Korkolopoulou ◽  
Georgios N. Panagopoulos ◽  
...  
Keyword(s):  
Skeletal Muscle ◽  
Case Report ◽  
Soft Tissue ◽  
Gastrointestinal Stromal Tumors ◽  
Review Of The Literature ◽  
Soft Tissue Metastasis ◽  
Mesenchymal Tumors ◽  
Stromal Tumors ◽  
Skeletal Muscle Metastasis ◽  
Muscle Metastasis

Gastrointestinal stromal tumors (GISTs) are the most common malignant mesenchymal tumors of the gastrointestinal tract. The most common sites of metastasis are the liver and the peritoneum, whereas metastasis to soft tissue is rare. The authors present the case of a 78-year-old male with a soft tissue metastasis of a GIST and the current literature is reviewed.

Sign in / Sign up

Export Citation Format

Share Document